Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by jimsenioron Apr 04, 2023 10:42am
183 Views
Post# 35378492

RE:Liability

RE:Liabilityto lonc17. I agree that he might be on thin ice if it is a bust. I do not think it is a bust. I do not think the share price is related to mBC being a bust. More likely a lack of clarity. We have AN without a CPI. We have MC stating at one point that AN might go with a CPI and then again they might not. The Roche mBC trial has never been crystal clear to me. The Pfizer/Merck trial with that annoying 90 day clause is is akin to a gordian knot; that is to say a jumble. One can only hope this can be untied.

As to AA  I guess that would be more likely to go to GOBLET, I am wondering how they could apply for AA for pela without Roche and tecentriq. If they have gone ahead with Roche, we would seem to have something solid.

Perhaps a knowledgeable shareholder can give some clarity to AA, and the mBC trials.

Must run MTG is on.
<< Previous
Bullboard Posts
Next >>